» Articles » PMID: 25563577

Perspectives of Physicians Regarding Screening Patients at Risk of Hepatocellular Carcinoma

Overview
Specialty Gastroenterology
Date 2015 Jan 8
PMID 25563577
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Screening patients at risk for hepatocellular carcinoma (HCC) facilitates early detection of disease, with improved outcome. The most common causes of HCC include chronic viral hepatitis infection-namely hepatitis B, hepatitis C, and cirrhosis. The aim of this study was to assess the awareness of screening among physicians involved in the management of patients at risk for HCC.

Methods: Three hundred physicians from three academic centers were invited to participate in a mailed survey questionnaire. The main outcome measure was physicians' knowledge of the current HCC screening guidelines. Demographic and clinical variables were obtained from the survey questionnaire.

Results: A total of 177 (59.0%) out of the 300 invited physicians responded to the survey questionnaire, including faculty members (n = 129), residents (n = 46), and fellows (n = 2). The specialty areas of the responding physicians were internal medicine (62.1%), family medicine (16.4%), gastroenterology (15.3%), oncology (3.4%) and others (2.8%). The number of physicians who performed HCC screening in patients with cirrhosis secondary to chronic hepatitis B and chronic hepatitis C infection were 163 (92.1%) and 167 (94.4%), respectively; 35.0% of them used alpha-fetoprotein (AFP) every 6 months, while 22.0% used imaging modalities every 6 months to screen for HCC. Further, 22 physicians (12.4%) did not check for serum AFP levels and 33 (18.6%) never used imaging to screen for HCC.

Conclusion: The majority of the participating physicians screen high-risk patients for HCC. However, the most appropriate modality of screening (i.e. imaging) is not employed by most physicians and there is greater reliance on AFP levels.

Citing Articles

Dedicated Automatic Recall Hepatocellular Cancer Surveillance Programme Demonstrates High Retention: A Population-Based Cohort Study.

Brahmania M, Congly S, Sachar Y, Burak K, Lethebe B, Szostakiwskyj J Liver Int. 2025; 45(3):e70020.

PMID: 39927626 PMC: 11809127. DOI: 10.1111/liv.70020.


Screening for Hepatocellular Carcinoma in Patients with Hepatitis B.

Sachar Y, Brahmania M, Dhanasekaran R, Congly S Viruses. 2021; 13(7).

PMID: 34372524 PMC: 8310362. DOI: 10.3390/v13071318.


Strategies to Improve Hepatocellular Carcinoma Surveillance in Veterans With Hepatitis B Infection.

Gowda C, Sheikh U, Maier A, Chang K, Kaplan D, Lo Re 3rd V Fed Pract. 2019; 34(Suppl 4):S30-S39.

PMID: 30766308 PMC: 6375474.


Barriers to Disease Monitoring and Liver Cancer Surveillance Among Patients with Chronic Hepatitis B in the United States.

Ispas S, So S, Toy M J Community Health. 2018; 44(3):610-625.

PMID: 30539329 DOI: 10.1007/s10900-018-00604-7.


Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis.

Tran S, Le A, Zhao C, Hoang J, Yasukawa L, Weber S BMJ Open Gastroenterol. 2018; 5(1):e000192.

PMID: 29607053 PMC: 5873543. DOI: 10.1136/bmjgast-2017-000192.

References
1.
Trevisani F, Cantarini M, Labate A, De Notariis S, Rapaccini G, Farinati F . Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol. 2004; 99(8):1470-6. DOI: 10.1111/j.1572-0241.2004.30137.x. View

2.
Topic A, Ljujic M, Radojkovic D . Alpha-1-antitrypsin in pathogenesis of hepatocellular carcinoma. Hepat Mon. 2012; 12(10 HCC):e7042. PMC: 3496874. DOI: 10.5812/hepatmon.7042. View

3.
Stravitz R, Heuman D, Chand N, Sterling R, Shiffman M, Luketic V . Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med. 2008; 121(2):119-26. DOI: 10.1016/j.amjmed.2007.09.020. View

4.
Cabibbo G, Maida M, Genco C, Parisi P, Peralta M, Antonucci M . Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. World J Hepatol. 2012; 4(9):256-61. PMC: 3468702. DOI: 10.4254/wjh.v4.i9.256. View

5.
Kuo Y, Lu S, Chen C, Cheng Y, Lin C, Hung C . Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer. 2010; 46(4):744-51. DOI: 10.1016/j.ejca.2009.12.018. View